The main active monomer of Dan'e-fukang soft extract, liquiritin, inhibits the inflammation and invasion of ectopic endometrial stromal cells through down-regulation of CCL2.
The study explored the mechanism of Dan'e-fukang soft extract in treating endometriosis (EMs) through network pharmacology. The main active ingredients of Dan'e-fukang soft extract were analyzed based on the traditional …
Exploring the mechanisms of luteolin in treating polycystic ovary syndrome and endometriosis via network pharmacology, molecular docking, and molecular dynamics simulation.
This study aims to elucidate the molecular mechanisms underlying luteolin's therapeutic effects on polycystic ovary syndrome (PCOS) and endometriosis (EM), thereby providing a theoretical foundation for developing novel treatment strategies. …
LINC00632 combines with ERα to target VISTA expression, ameliorating endometriosis progression.
Endometriosis, a prevalent gynecological disease affecting women's health, involves altered immune function. This study investigates the immune checkpoint protein, V-domain immunoglobulin suppressor of T cell activation (VISTA) as a therapeutic …
Study on material basis and network mechanism of the Guizhi Fuling pills in the treatment of endometriosis and endometrial polyps.
To explore the material basis and network mechanism of the Guizhi Fuling pills in the treatment of endometriosis and endometrial polyps based on network pharmacology and machine learning. The effective …
Polyphenol-Rich Wild Fruits of the Indian Himalayas as a Potential Nutraceutical Candidate for the Management of Endometriosis: A Review.
India, home to 4 biodiversity hotspots, hosts 675 wild species used for nutritional and therapeutic purposes. Wild edible fruits are highly valuable for their rich content of health-beneficial compounds, such …
Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology to Reveal the Material Basis and Mechanism of Juan-tong-yin in the Treatment of Endometriosis.
Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.
Comments on "Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial".